Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
These medications focus on gradual weight loss and improving metabolism over time
Some individuals may experience digestive side effects when starting GLP-1 therapy, including nausea, bloating, early fullness, constipation, or loose stools
Key risks include: Delayed appropriate treatment : Patients with type 2 diabetes or obesity may postpone evidence-based interventions while using ineffective patches, potentially worsening metabolic control and increasing cardiovascular risk Undisclosed ingredients : While supplement manufacturers must follow current Good Manufacturing Practices, quality control varies widely
Additionally, the administration of oral GLP-1 drugs requires strict guidance: for example, semaglutide must be taken on an empty stomach in the morning, with no more than 120 mL of water, and patients must wait at least 30 minutes before having breakfast